4-valent HPV vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Child Health, Hungary, Shanghai Bovax Biotechnology Co., Ltd.

Conditions

AISCIN1CIN2CIN3Cervical CancerGenital WartRecurrent Respiratory PapillomatosisVIN 1

Phase 3

4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children

National Institute of Child Health, HungaryRecurrent Respiratory Papillomatosis

Start: 2014-02-28End: 2017-02-28Target: 20Updated: 2013-11-27

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

CompletedNCT04425291

Shanghai Bovax Biotechnology Co., Ltd.AIS, Cervical Cancer, CIN1 +11

Start: 2020-05-28End: 2021-09-06Updated: 2022-02-25